随着国亮新材上市在即，截至1月22日，北交所月内上市的新股将达到3只。 对比此前情况，北交所的新股发行是否出现提速迹象？ 北交所的上市审核、新股发行正在密集开展，一周之内就有3场上市委会议、2只新股上市，以及2只新 股申购。 1月21日，爱舍伦（920050.BJ）登录北交所，上市首日大涨175.59%，当日报收44.04元/股，换手率达到 78.23%。当天，美德乐（920119.BJ）开启申购，每股发行价为41.88元，市盈率为14.99倍。明日（1月 22日），国亮新材（920076.BJ）将登陆北交所。 审核端，据北交所官网，本周（1月19日至23日），该所将共计召开3场上市委审议会议，至此，北交所 月内将安排了8场上市委会议，并连续出现"一周三审"的情况。 如何看待近期北交所的发行审核节奏？北京南山投资创始人周运南告诉第一财经，北交所新股冻资规模 持续保持高位，并有望继续冲高，市场释放出赚钱效应，市场高度期待北交所的新股上市提速、高质量 扩容。另有分析认为，结合2025年上市审核情况，北交所IPO正呈现"加速跑"态势。 一周三审、2股上市、2股打新 本周上市的2只新股爱舍伦、国亮新材，IPO申请均在 ...

Group 1 - The core point of the news is the issuance of new stocks in the market, with a total of 8 companies raising a cumulative amount of 7.498 billion yuan so far this year, averaging 937 million yuan per company [1][2] - The newly issued stocks include 2 from the Shanghai main board, 1 from the Sci-Tech Innovation Board, and 5 from the Beijing Stock Exchange, with total fundraising amounts of 4.158 billion yuan, 1.561 billion yuan, and 1.779 billion yuan respectively [1] - The company with the highest fundraising amount is Zhenstone Co., Ltd., raising 2.919 billion yuan primarily for the construction of fiberglass product production bases and composite material production bases [1] Group 2 - The average initial issuance price of new stocks this year is 28.82 yuan, with the highest price being 92.18 yuan for Hengyun Chang, followed by Meidele and Nongda Technology at 41.88 yuan and 25.00 yuan respectively [2] - The geographical distribution of newly issued stocks shows a concentration in Zhejiang, Liaoning, and Jiangsu, with the highest fundraising amounts from Zhejiang, Guangdong, and Chongqing at 3.163 billion yuan, 1.561 billion yuan, and 1.240 billion yuan respectively [2] - The detailed list of newly issued stocks includes Zhenstone Co., Ltd. with 26,105.50 million shares at 11.18 yuan raising 2.919 billion yuan, and Hengyun Chang with 1,693.06 million shares at 92.18 yuan raising 1.561 billion yuan [2]

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Core Viewpoint - Aishalon Medical Technology Group Co., Ltd. (stock code: 920050.BJ) was listed on the Beijing Stock Exchange, opening at 48.88 yuan and closing at 44.04 yuan, with a significant increase of 175.59% and a total market capitalization of 2.981 billion yuan [1]. Company Overview - Aishalon focuses on the medical health sector, primarily engaged in the research, production, and sales of disposable medical consumables for rehabilitation care and medical protection [1]. - The company provides products to internationally renowned medical device brands through ODM/OEM methods [1]. Shareholding Structure - The controlling shareholder is Jiangsu Novick Technology Investment Co., Ltd., with Zhang Yong as the actual controller, holding a total of 88.69% of the company's shares [1][2]. - After the issuance, Zhang Yong directly holds 1,000,000 shares (1.48%) and indirectly controls 45,017,025 shares (66.52%) [2]. Financial Performance - In 2022, 2023, and 2024, Aishalon's revenue was 573.56 million yuan, 574.66 million yuan, and 691.64 million yuan, respectively, with net profits of 62.80 million yuan, 66.94 million yuan, and 80.61 million yuan [7]. - For the first half of 2025, the revenue was 438.20 million yuan, with a net profit of 49.43 million yuan [8]. - The company reported a revenue of 68.96 million yuan for the first nine months of 2025, a year-on-year increase of 42.84%, and a net profit of 7.31 million yuan, up 26.98% [11]. Fundraising and Investment Projects - Aishalon raised a total of 270.38 million yuan, with a net amount of 240.18 million yuan allocated for the construction of the Caprol Public Health Medical Supplies Industrial Park [5]. - The total investment for the Caprol project is 670.46 million yuan, with 300 million yuan funded through this issuance [6]. Future Projections - The company expects 2025 revenue to be between 889.82 million yuan and 939.87 million yuan, representing a growth of 28.65% to 35.89% compared to 2024 [12]. - The projected net profit for 2025 is estimated to be between 89.29 million yuan and 98.48 million yuan, indicating a growth of 10.63% to 22.01% [12].

Core Viewpoint - Jiangsu Aisheren Medical Technology Group Co., Ltd. successfully went public on the Beijing Stock Exchange, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District on the North Exchange [1][6]. Company Overview - Aisheren focuses on the medical health sector, primarily engaged in the research, production, and sales of disposable medical consumables used in rehabilitation care and medical protection [3][8]. - The company provides products through ODM/OEM methods for internationally renowned medical device brands, continuously expanding its product line to include disinfection, home protection, and emergency protection [3][9]. - Aisheren has obtained several certifications, including ISO13485:2016, EU CE certification, and US FDA registration, meeting high global standards for medical consumables [3][9]. Future Plans - The successful IPO will serve as a catalyst for Aisheren to enhance existing production capacity and increase investment in the research and development of new medical consumables [3][9]. - The company aims to actively expand its sterilization business and continuously optimize product quality and service levels [3][9]. - Aisheren plans to leverage the Belt and Road Initiative to deepen its presence in the global medical dressing market, contributing more Chinese wisdom and strength to global healthcare [3][9]. Role of Dongwu Securities - Dongwu Securities acted as the sponsor and underwriter for Aisheren's IPO, showcasing its expertise in the medical consumables sector and enhancing its brand influence in the North Exchange [5][11]. - The firm has successfully sponsored and underwritten 48 companies in Suzhou, with a nearly 50% market share of Suzhou companies listed on the North Exchange [5][11]. - Dongwu Securities aims to continue its commitment to high-quality development and to advance towards becoming a leading investment bank characterized by specialization, market orientation, technological advancement, and internationalization [5][11].

Core Insights - Aishalon Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District [2] - The company's stock opened with a significant increase of 224.78%, reaching a total market capitalization of 3.49 billion yuan [2] Company Overview - Aishalon Medical focuses on the research, production, and sales of disposable medical consumables in the fields of rehabilitation care and surgical infection control [3] - The company has established long-term strategic partnerships with several international medical device brands, including Medline Group from the U.S., Zarys Group from Poland, and Sejong Healthcare from South Korea [3] - Aishalon is recognized as the largest manufacturer of medical care pads in China, with annual output value exceeding 500 million yuan from 2022 to 2024, positioning itself among the top players in the domestic medical dressing industry [3] Financial Performance - From 2022 to 2024, Aishalon's operating revenue grew from 574 million yuan to 692 million yuan, while net profit increased from 63 million yuan to 81 million yuan, demonstrating a steady compound annual growth rate [4] - For the first nine months of 2025, the company achieved an operating revenue of 689 million yuan, a year-on-year increase of 42.84%, and a net profit of 73 million yuan, up 27.50% from the previous year [4] - The company has maintained a high proportion of overseas sales revenue, which reached 96.54% in the first half of 2025, indicating its strong role in the global supply chain [4] Industry Context - The medical dressing industry is characterized by rigid demand, driven by global aging populations, increasing surgical volumes, and heightened infection control awareness [5] - The market for medical dressings is expected to continue growing steadily, with a trend towards high-quality, multifunctional, and disposable products [5] Growth Strategy - Aishalon plans to use the funds raised from its IPO to invest in the "Kaipule Public Health Medical Supplies Industrial Park" project, aimed at expanding production capacity and developing new product lines [6] - The company is transitioning from a single dressing production focus to a broader medical consumables manufacturing and service platform, which is expected to reduce dependency on single products and clients [6] - Aishalon is also expanding its global production footprint, with existing bases in Thailand and plans for new facilities in Morocco, showcasing its strategic vision to adapt to international trade dynamics and cost pressures [6]

Core Viewpoint - Aisheren (BJ:920050) was listed on the Beijing Stock Exchange on January 21, with an opening increase of 224.78% and a total market capitalization of 3.49 billion yuan [2] Company Overview - Aisheren specializes in the research, production, and sales of disposable medical consumables used in professional rehabilitation care and medical protection [2] - The company's product range includes rehabilitation care products and surgical infection control products, offering items such as medical care pads, ice bags, surgical gowns, surgical drapes, and surgical kits [2] Financial Performance - Aisheren's total assets increased from approximately 837.99 million yuan in 2022 to about 1.20 billion yuan by June 30, 2025 [3] - Shareholder equity rose from approximately 607.31 million yuan in 2022 to about 795.19 million yuan by June 30, 2025 [3] - The company's revenue for the years 2022 to 2025 (first half) was reported as 574.66 million yuan, 575.00 million yuan, 691.64 million yuan, and 438.20 million yuan respectively [3] - Net profit figures for the same periods were approximately 62.80 million yuan, 66.94 million yuan, 80.61 million yuan, and 49.43 million yuan [3] Future Projections - For the fiscal year 2025, Aisheren expects revenue to be between 890 million yuan and 940 million yuan, representing a year-on-year growth of approximately 28.65% to 35.89% [4] - The projected net profit attributable to shareholders is estimated to be between 89.29 million yuan and 98.48 million yuan, with a growth rate of about 10.63% to 22.01% [4] - The company anticipates that its net profit after deducting non-recurring gains and losses will be between 86.11 million yuan and 95.29 million yuan, reflecting a growth of 19.37% to 32.11% [4] Customer Concentration - Aisheren's top five customers accounted for 81.99% to 88.40% of total sales revenue during the reporting periods, indicating a high level of customer concentration [4] - The largest customer, Medline Group, represented 71.51% to 77.73% of total sales revenue across the same periods [4] Sales Distribution - The majority of Aisheren's revenue comes from international sales, with overseas sales accounting for 90.99% to 96.54% of total revenue during the reporting periods [4] - The company's products are primarily sold in the United States, Europe, and South Korea [4] Ownership Structure - Prior to the IPO, Zhang Yong directly held 1.97% of the company's shares and indirectly controlled 79.58% through the controlling shareholder, Jiangsu Novick [5] - Zhang Yong, who is the chairman and general manager, has a total control of 88.69% of the company's shares [5]

Company and Industry Summary Company: Aisheren (920050) Key Points - **Core Business Focus**: Aisheren specializes in medical dressings, particularly in rehabilitation care and surgical infection control products. The company emphasizes a "core customer" strategy, collaborating closely with major clients to iteratively develop products based on demand and optimize manufacturing processes [1][2]. - **Major Client**: Medline Group has been the largest customer from 2022 to 2024, accounting for over 70% of Aisheren's revenue. This strong client relationship is pivotal for the company's revenue stability and growth [3]. - **Market Trends**: Two primary growth drivers are identified: 1. Enhanced safety and hygiene standards in operating rooms, aligning with practices in Europe and the US. 2. Increased demand for elderly care, opening up opportunities in the consumer market [3]. - **Medline's Global Position**: Medline is recognized as the largest manufacturer and distributor of surgical supplies globally and the fourth largest medical device company. It went public on NASDAQ in December 2025, raising approximately $2.26 billion, which will be invested in local markets and global expansion, as well as supply chain upgrades [3]. - **Capacity Expansion**: Aisheren faced capacity constraints before 2024, but with the commissioning of a factory in Thailand, revenue growth is expected to accelerate. For 2024, revenue and profit growth rates are projected to increase significantly, with year-on-year growth of 20.4% and 20.5% respectively, and for Q3 2025, growth rates are expected to be 42.8% and 27.5% respectively [3]. - **Future Production Plans**: The company plans to continue expanding production capacity in 2026 and 2027, with expected increases of 50% and 30% respectively. New facilities in various locations, including domestic and international sites, will produce customized products, including precision urine bags [3]. - **Investment Outlook**: The low-value consumables market is a necessity for medical institutions, and the global market is steadily expanding. International leading brands are increasing their international business, and contract manufacturers are likely to benefit from shared market expansion opportunities [3].

Group 1 - Aishalon (920050) has been listed on the Beijing Stock Exchange, focusing on the medical health sector, specifically in the research, production, and sales of disposable medical consumables for rehabilitation care and medical protection [1] - The company is controlled by Jiangsu Novik Technology Investment Co., Ltd., with Zhang Yong as the actual controller, holding a total of 88.69% of the company's equity [1] - After the issuance, Zhang Yong directly holds 1,000,000 shares (1.48%) and indirectly holds 40,394,700 shares (59.69%) through Jiangsu Novik, along with additional shares through partnerships, totaling 45,017,025 shares (66.52%) of voting rights [2] Group 2 - The total amount raised from the issuance is 270.38 million yuan, with a net amount of 240.18 million yuan after deducting non-tax issuance costs, which will be used for the construction of the Caple Public Health Medical Supplies Industrial Park project [2]

每经AI快讯，1月21日，新股N爱舍伦在北交所上市，开盘大涨205.88%，报48.88元/股，当前市值33亿 元。 ...